Assessment of safety of additional transplantation of autologous bone marrow mononuclear cells in the combined treatment of coronary heart disease. Results from a randomized, blind, placebo-controlled trial (TAMIS)
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.